FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080852976> ?p ?o ?g. }

• W3080852976 endingPage "77" @default.
• W3080852976 startingPage "69" @default.
• W3080852976 abstract "Leukemia, as a part of hemoblastosises, is a malignant blood system disease, which is characterized by bone marrow damage, caused by leukemic stem cells, which appear due to disruption of self-renewal and differentiation of hempoetic stem cells and predecessor cells. In their turn, hemoblastoses are divided into two groups: bone marrow (acute leukemia, chronical leukemia, paraproteinemic hemoblastoses) and outside bone marrow (lymphogranulomatosis, or Hodgkin lymphoma, and non-Hodgkin malignant mymphomas).&#x0D; Nowadays in Ukraine, different kinds of leukemia are cured by various drugs, which have many side effects. Increase in effectivity of chemotherapy of tumor disease is primarily related to creation of new antitumor drugs of selective action. Which is why search for biologically active compounds with antitumor activity is a perspective direction in creation of new drugs.&#x0D; Aim of this work was synthesis of compounds with potential antitumor properties in a variety of [4-(41-chlorophenyl)-5,6,7,8-tetrahydro-2,2a,8a-triazacyclopenta[c,d]-azulen-1-yl-methyl]-para-tolylamin derivatives.&#x0D; As the objects of our studies, we have picked the derivatives of [4-(41-chlorophenyl)-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[c,d]-azulen-1-yl-methyl]-para-tolilamin (8 and 10 a, b). [4-(41-Chlorphenyl)-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[c,d]azulen-1-yl-methyl]-para-tolylamin (8) was obtained by boiling of equimolar quantities of 3-(41-methylphenyl)aminomethyl-6,7,8,9-tetrahydro-5Н-[1,2,4]triazolo[4,3-a]azepin (5) and α-brom-4-chloracetophenon in ethylacetate. Thioamides (10 a, b) were obtained by interaction of amin (8) with corresponding arylisothiocyanates (9 а, b) in dry benzene.&#x0D; Antitumor activity of [4-(41-chlorphenyl)-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[c,d]azulen-1-yl-methyl]-para-tolylamin (8) was studied in National Cancer Institute of Health, USA within Development Therapeutic Program.&#x0D; In experimental conditions [4-(41-chlorphenyl)-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[c,d]azulen-1-yl-methyl]-para-tolylamin (8) showed ability to inhibit growth of cancerous leukemia cells of CCRF-CEM, HL-60(TB), K-562, MOLT-4, RPMI-8226 and SR lines, higher than standard – 5-fluorouracil. Towards HL-60(TB) cells [4-(41-chlorphenyl)-5,6,7,8-tetrahydro-2,2а,8а- triazacyclopenta[c,d]azulen-1-yl-methyl]-para-tolylamin exceeds standard in effectivity by 64.68%. For K-562, MOLT-4, RPMI-8226 and SR cells, those numbers are equal to: 85.88%, 84.95%, 42.10% and 36.82% correspondingly. Towards CCRF-CEM cells, this compound not only inhibits cell growth and division, but also destroys them by 20.34%.&#x0D; Thus conducted studies confirm perceptivity of search for compounds with antitumor action on the basis of [4-(41-chlorophenyl)-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[c,d]azulen-1-yl­methyl]-para-tolylamin." @default.
• W3080852976 created "2020-09-01" @default.
• W3080852976 creator A5028065296 @default.
• W3080852976 creator A5043544921 @default.
• W3080852976 creator A5045074564 @default.
• W3080852976 creator A5049345305 @default.
• W3080852976 creator A5079295688 @default.
• W3080852976 creator A5084491495 @default.
• W3080852976 date "2020-07-30" @default.
• W3080852976 modified "2023-09-25" @default.
• W3080852976 title "Synthesis and anti-tumor properties of derivatives [4- (41-chlorophenyl)-5,6,7,8-tetrahydro-2,2a,8a-triazacyclopenta[c,d]azulen-1-yl-metil]-para-tolylamine" @default.
• W3080852976 doi "https://doi.org/10.32352/0367-3057.4.20.07" @default.
• W3080852976 hasPublicationYear "2020" @default.
• W3080852976 type Work @default.
• W3080852976 sameAs 3080852976 @default.
• W3080852976 citedByCount "0" @default.
• W3080852976 crossrefType "journal-article" @default.
• W3080852976 hasAuthorship W3080852976A5028065296 @default.
• W3080852976 hasAuthorship W3080852976A5043544921 @default.
• W3080852976 hasAuthorship W3080852976A5045074564 @default.
• W3080852976 hasAuthorship W3080852976A5049345305 @default.
• W3080852976 hasAuthorship W3080852976A5079295688 @default.
• W3080852976 hasAuthorship W3080852976A5084491495 @default.
• W3080852976 hasBestOaLocation W30808529761 @default.
• W3080852976 hasConcept C126322002 @default.
• W3080852976 hasConcept C185592680 @default.
• W3080852976 hasConcept C2776863199 @default.
• W3080852976 hasConcept C2778461978 @default.
• W3080852976 hasConcept C2779338263 @default.
• W3080852976 hasConcept C2780007613 @default.
• W3080852976 hasConcept C3017763353 @default.
• W3080852976 hasConcept C502942594 @default.
• W3080852976 hasConcept C71924100 @default.
• W3080852976 hasConcept C98274493 @default.
• W3080852976 hasConceptScore W3080852976C126322002 @default.
• W3080852976 hasConceptScore W3080852976C185592680 @default.
• W3080852976 hasConceptScore W3080852976C2776863199 @default.
• W3080852976 hasConceptScore W3080852976C2778461978 @default.
• W3080852976 hasConceptScore W3080852976C2779338263 @default.
• W3080852976 hasConceptScore W3080852976C2780007613 @default.
• W3080852976 hasConceptScore W3080852976C3017763353 @default.
• W3080852976 hasConceptScore W3080852976C502942594 @default.
• W3080852976 hasConceptScore W3080852976C71924100 @default.
• W3080852976 hasConceptScore W3080852976C98274493 @default.
• W3080852976 hasIssue "4" @default.
• W3080852976 hasLocation W30808529761 @default.
• W3080852976 hasOpenAccess W3080852976 @default.
• W3080852976 hasPrimaryLocation W30808529761 @default.
• W3080852976 hasRelatedWork W2045210690 @default.
• W3080852976 hasRelatedWork W2065008538 @default.
• W3080852976 hasRelatedWork W2328209750 @default.
• W3080852976 hasRelatedWork W2352793801 @default.
• W3080852976 hasRelatedWork W2357201540 @default.
• W3080852976 hasRelatedWork W2370729850 @default.
• W3080852976 hasRelatedWork W2371537133 @default.
• W3080852976 hasRelatedWork W2372435973 @default.
• W3080852976 hasRelatedWork W2380660014 @default.
• W3080852976 hasRelatedWork W2410819865 @default.
• W3080852976 isParatext "false" @default.
• W3080852976 isRetracted "false" @default.
• W3080852976 magId "3080852976" @default.
• W3080852976 workType "article" @default.